Key Considerations When Acquiring A Cell And Gene Biotech

Insights From Project Farma

Stakeholders looking to gain deeper insights into potential cell and gene therapy candidates and optimize R&D strategies can employ several strategies to inform portfolio management decisions.  

Key Areas To Scrutinize When Considering A CGT Acquisition • Source: Shutterstock
About The Authors

Anshul Mangal is co-founder and president of Project Farma and Precision for Medicine’s Manufacturing Solutions, as well as a board member at the Alliance for Regenerative Medicines, Alliance for mRNA Medicines and IQHQ. Prior to his tenure at Project Farma, Mangal was a patent litigator at Jones Day.

As executive vice president of Project Farma, Tony Khoury spearheaded the firm’s growth in the biotech space with a focus on next-generation medicines. He has supported the industrialization of many of the first FDA-approved advanced therapies and led the creation of Project Farma’s Advanced Therapy Manufacturing Playbook.

The cell and gene therapy (CGT) space continues to make headlines and stand out as a beacon of innovation and opportunity, attracting considerable attention from investors and biotech developers. Reports consistently underscore the industry's potential, with its robust growth trajectory remaining resilient even amidst broader investment downturns. In 2023 alone, investments totaled $11.7bn.

CGTs have emerged at the forefront of biotech, offering promising solutions to address a number of previously unmet medical needs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Growth

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By 

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

More from In Vivo

AI In Health Delivery: Patients Most Confident When HCPs Are In Charge

 
• By 

Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By 

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.